Finally, the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the Veterans Affairs nephropathy in Diabetes (VA Nephron D) study showed that the combination of ACE inhibition and ARB together lead to more adverse events with little additional benefit. This evidence concerns the gene ACE and diabetes mellitus.